Internal Medicine, Hematology & Oncology · Anderson, IN
NPI
1730136953
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1340 N Madison Ave
Anderson, IN, 46011
Phone (765) 298-1620
Groups this clinician bills Medicare through
Medicare paid, 2024
$224K
3,162 services
Medicare patients, 2024
620
Average age 73
Drug cost, 2024
$5.8M
2,990 prescriptions
Company payments, 2025
$647
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tahir A Naqvi was code 99214 (office e&m - established), 2,164 times for 508 patients. In total Tahir A Naqvi billed 3,162 services in 20 codes, and Medicare paid $224K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-08-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 2,164 | 508 | $69.09 | $150K |
| 99213 Office E&M - Established | Facility | 282 | 194 | $45.38 | $13K |
| 99232 Hospital E&M - Subsequent | Facility | 242 | 79 | $59.03 | $14K |
| 99215 Office E&M - Established | Facility | 197 | 92 | $105.03 | $21K |
| 99204 Office E&M - New | Facility | 81 | 81 | $92.17 | $7,466 |
| 99223 Hospital E&M - Initial | Facility | 76 | 69 | $129.64 | $9,853 |
| 38222 Other Organ Systems | Facility | 27 | 27 | $51.42 | $1,388 |
| 99233 Hospital E&M - Subsequent | Facility | 22 | 21 | $88.78 | $1,953 |
| 99205 Office E&M - New | Facility | 19 | 19 | $131.65 | $2,501 |
| 99222 Hospital E&M - Initial | Facility | 17 | 15 | $98.09 | $1,668 |
| 99214 Office E&M - Established | Office | 12 | 12 | $72.75 | $873 |
By year: 2022 $255K for 3,220 services; 2023 $254K for 3,496 services; 2024 $224K for 3,162 services.
Medicare prescription drug claims, 2024
In 2024, the drug Tahir A Naqvi prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 341 prescriptions and refills. In total Tahir A Naqvi wrote 2,990 Medicare prescriptions that cost $5.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 341 | 344 | 90 | $14K |
| Anastrozole Generic | 281 | 629 | 83 | $3,506 |
| Ondansetron Odt Ondansetron | 193 | 196 | 119 | $4,042 |
| Prochlorperazine Maleate Generic | 177 | 177 | 102 | $3,031 |
| Morphine Sulfate Er Morphine Sulfate | 104 | 104 | 26 | $3,873 |
| Cyanocobalamin Injection Cyanocobalamin (Vitamin B-12) | 99 | 207 | 45 | $1,469 |
| Dexamethasone Generic | 90 | 90 | 31 | $1,545 |
| Folic Acid Generic | 80 | 193 | 30 | $326 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 77 | 77 | 61 | $929 |
| Clonidine Hcl Generic | 66 | 90 | 15 | $148 |
| Eliquis Apixaban | 64 | 90 | 18 | $51K |
| Testosterone Cypionate Generic | 63 | 134 | 27 | $2,344 |
| Lorazepam Generic | 62 | 62 | 31 | $111 |
| Prednisone Generic | 61 | 73 | 25 | $215 |
| Ninlaro Ixazomib Citrate | 48 | 48 | Under 11 | $593K |
Brand drugs: 558 claims; generic drugs: 2,432 claims; opioid claims: 571.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tahir A Naqvi $647 ($647 in general payments such as food, travel and fees) from 22 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $78.62.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 3 | $78.62 |
| Daiichi Sankyo Inc. 4568.T | 1 | $74.99 |
| Merck Sharp & Dohme LLC MRK | 2 | $45.37 |
| Abbvie Inc. ABBV | 2 | $40.76 |
| Janssen Biotech, Inc. JNJ | 2 | $35.94 |
| Karyopharm Therapeutics Inc. KPTI | 2 | $31.52 |
| Lilly USA, LLC LLY | 1 | $27.53 |
| Kite Pharma, Inc. GILD | 1 | $26.24 |
| Janssen Pharmaceuticals, Inc JNJ | 1 | $25.72 |
| Sirtex Medical Inc | 1 | $25.23 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.